JPMorgan Chase & Co. Initiates Coverage on Aktis Oncology (NASDAQ:AKTS)

Analysts at JPMorgan Chase & Co. initiated coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note issued on Tuesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $30.00 price target on the technology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 50.60% from the company’s previous close.

A number of other research analysts also recently issued reports on AKTS. Bank of America started coverage on shares of Aktis Oncology in a research report on Tuesday. They set a “buy” rating and a $34.00 target price for the company. Leerink Partners began coverage on Aktis Oncology in a research note on Tuesday. They set an “outperform” rating and a $31.00 price objective for the company. TD Cowen initiated coverage on Aktis Oncology in a research note on Tuesday. They issued a “buy” rating on the stock. Finally, Wall Street Zen raised Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Aktis Oncology currently has an average rating of “Buy” and a consensus price target of $31.67.

Aktis Oncology Stock Performance

Shares of NASDAQ AKTS opened at $19.92 on Tuesday. Aktis Oncology has a 12 month low of $18.02 and a 12 month high of $29.16.

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc acquired 2,222,222 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $39,999,996.00. Following the completion of the transaction, the director owned 4,348,658 shares in the company, valued at approximately $78,275,844. The trade was a 104.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ansbert Gadicke bought 1,112,777 shares of the stock in a transaction dated Monday, January 12th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the purchase, the insider owned 10,260,064 shares in the company, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 6,117,776 shares of company stock valued at $110,119,968 in the last ninety days. Company insiders own 3.30% of the company’s stock.

Aktis Oncology News Roundup

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Bank of America initiated coverage with a “buy” rating and a $34.00 price target (implies ~71% upside vs. the referenced price), providing a sizeable bullish catalyst for AKTS.
• Positive Sentiment: Leerink Partners started coverage with an “outperform” rating and a $31.00 target (roughly 56% upside), adding another institutional endorsement that could attract investor interest. Article Title
• Positive Sentiment: JPMorgan initiated with an “overweight” rating and a $30.00 price target (~51% upside), adding further sell‑side conviction that AKTS’s pipeline and platform could support higher valuations. Article Title
• Positive Sentiment: TD Cowen (covered in TipRanks and The Fly writeups) initiated coverage with a Buy rating and highlighted Aktis’s differentiated miniprotein radiopharma platform and multi‑billion dollar sales potential — a thematic, research‑driven positive for investor sentiment. Article Title Article Title
• Neutral Sentiment: A short‑interest report in the record shows essentially zero reported short interest (entries list 0 shares and an uninformative NaN change), so short covering or aggressive short selling does not appear to explain today’s move.
• Negative Sentiment: Despite the bullish analyst initiations, the stock is trading down on the day with volume slightly below its average — a sign of short‑term profit taking or sector/market weakness outweighing the positive analyst news in the near term.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.